Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 4/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20966632 | 0.98 | HRH3 (0.47) | HRH3HRH4CPB2CPB1 | |
| SCHEMBL25866505 | 0.98 | HRH3 (0.47) | HRH3HRH4CPB2CPB1 | |
| SCHEMBL14415990 | 0.86 | HRH3 (0.54) | HRH3HRH4CPB2CPB1 | |
| SCHEMBL22692972 | 0.84 | HRH3 (0.56) | HRH3HRH4CPB2CPB1 | |
| SCHEMBL10613000 | 0.84 | HRH3 (0.56) | HRH3HRH4CPB2CPB1 | |
| SCHEMBL8818261 | 0.81 | HRH3 (0.48) | HRH3HRH4CPB2CPB1 | |
| SCHEMBL14464497 | 0.80 | HRH3 (0.59) | HRH3HRH4CPB2CPB1 | |
| SCHEMBL26215004 | 0.78 | HRH3 (0.47) | HRH3HRH4CPB2CPB1 | |
| SCHEMBL28181817 | 0.77 | HRH3 (0.53) | HRH3HRH4CPB2CPB1 | |
| SCHEMBL11667436 | 0.75 | HRH3 (0.58) | HRH3HRH4CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | NOCION THERAPEUTICS INC (US) | 2021-03-04 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20180086735-A1 | N-CYCLOALKYL-N-(BIHETEROCYCLYETHYLENE)-(THIO)CARBOXAMIDE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086735-A1 | N-CYCLOALKYL-N-(BIHETEROCYCLYETHYLENE)-(THIO)CARBOXAMIDE DERIVATIVES | CBR3, CYP51A1, CBR1 | HRH3 2455/4885HRH4 1847/4885CPB2 1587/4885 |
| US-20210061763-A1 | CHARGED ION CHANNEL BLOCKERS AND METHODS FOR USE | TRPV1, TRPV2, TRPV5 | HRH3 142/4885HRH4 135/4885CPB2 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.